Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Platify 75 Eltrombopag Tablets 75 mg
Platify 75 Eltrombopag Tablets 75 mg is an effective therapeutic option for patients with low platelet counts due to chronic immune thrombocytopenia (ITP) or liver disease. Eltrombopag, the active ingredient, works by stimulating the thrombopoietin receptor, which promotes platelet production in the bone marrow. This results in increased platelet counts, improving the patient's condition and reducing the risk of bleeding.
Uses of Platify 75 Eltrombopag Tablets 75 mg
Chronic Immune Thrombocytopenia (ITP): Increases platelet counts in patients with ITP who have not responded adequately to other treatments.
Thrombocytopenia Associated with Chronic Liver Disease: Helps improve platelet counts in patients with chronic liver disease who experience low platelet levels.
Prevention of Bleeding: By increasing platelet counts, Platify reduces the risk of bleeding and related complications in patients with low platelet counts.
Benefits of Platify 75 Eltrombopag Tablets 75 mg
Effective Platelet Count Increase: Significantly raises platelet counts, improving overall patient condition and reducing the risk of bleeding.
Convenient Dosage Form: Available in a 75 mg tablet form, making it easy to administer and incorporate into daily treatment regimens.
Long-Term Management: Provides effective long-term management of low platelet counts, contributing to improved quality of life.
Targeted Action: Specifically targets the thrombopoietin receptor, offering a precise approach to increasing platelet production.
Well-Tolerated: Generally well-tolerated with a favorable safety profile, minimizing the risk of severe adverse effects.
Mechanism of Action of Platify 75 Eltrombopag Tablets 75 mg
Eltrombopag acts as a thrombopoietin receptor agonist, binding to and activating the thrombopoietin receptor on megakaryocytes and progenitor cells in the bone marrow. This activation stimulates the production of platelets from megakaryocytes, thereby increasing platelet counts in the bloodstream. By promoting platelet production, Eltrombopag helps to correct low platelet levels and mitigate the risk of bleeding complications.